Download PDF
Der Klinikarzt 2006; 35(2): 57-61
DOI: 10.1055/s-2006-933683
In diesem Monat

© Georg Thieme Verlag Stuttgart · New York

Nicht rein hormonell bedingt - Prämature Atherosklerose bei Männern - Was ist die Ursache?

Not Alone on Basis of Hormonal Status - Premature Atherosclerosis in Men: What is the Cause?D. Strödter1
  • 1Innere Medizin/Kardiologie, Medizinische Klinik I, Universitätsklinik Gießen (Direktor: Prof. Dr. H. Tillmanns)
Further Information

Publication History

Publication Date:
23 February 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die koronare Herzerkrankung (KHK) ist die Haupttodesursache bei Männern wie bei Frauen. Männer entwickeln sie aufgrund einer prämaturen Atherosklerose jedoch zehn Jahre früher als Frauen. Dies verkürzt die Lebenserwartung des Mannes um rund sechs Jahre. Bei gleichem Blutdruckwert oder Cholesterinwert haben jüngere und mittelalte Männer ein doppelt so hohes kardiovaskuläres Risiko wie Frauen - oder das gleiche Risiko wie um zehn Jahre ältere Frauen. Demnach ist das männliche Geschlecht neben dem Alter ein eigenständiger wesentlicher Risikofaktor. Die geschlechtsspezifische Hormonsituation (Sexualhormone) kann jedoch die beschriebene Geschlechterdifferenz bei atherosklerotischen Folgeerkrankungen nicht erklären. Die bisherige Datenlage erlaubt zurzeit keine definitive Erklärung der prämaturen Atherosklerose beim Mann.

Summary

Coronary artery disease (CAD) is the leading cause of death in men and women. But, compared to women men develop heart disease about ten years earlier, leading to an average life expectancy six years less than in women. What is the cause? The cause is premature atherosclerosis in men. Compared to women the same value of blood pressure or cholesterol results in a doubling of cardiovascular risk in men - or in the same risk as ten year older women - having the same risk factor value. Thus, besides age the most important cardiovascular risk factor is male sex, an irreversible one. But, the gender difference in coronary artery disease cannot be explained on the basis of endogenous sex hormone exposure. Till today, current evidence does not allow any definitive explanation of the premature atherosclerosis in men.

Key Words

premature atherosclerosis - gender gap - male cardiovascular risk

Literatur

  • 1 1999 World Health Organization - International Society of Hypertension Guidelines for the management of hypertension. . Guidelines Subcommittee.  J Hypertens. 1999;  17 151-183
    PubMedGoogle Scholar
  • 2 Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review.  Atherosclerosis. 1996;  125 1-13
    CrossrefPubMedGoogle Scholar
  • 3 Assmann G, Cullen P, Jossa F. et al. . Coronary heart disease: reducing the risk. The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task Force for the Prevention of Coronary Heart Disease.  Arterioscler Thromb Vasc Biol. 1999;  19 1819-1824
    PubMedGoogle Scholar
  • 4 Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study.  Circulation. 2002;  105 310-315
    CrossrefPubMedGoogle Scholar
  • 5 Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population based study.  Circulation. 1988;  78 539-545
    PubMedGoogle Scholar
  • 6 Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys lecture.  Circulation. 1997;  95 252-264
    CrossrefPubMedGoogle Scholar
  • 7 Burt VL, Whelton P, Rocella EJ. et al. . 1995 prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991.  Hypertension. 1995;  25 305-313
    Google Scholar
  • 8 Collins P, Stevenson JC, Mosca L. Spotlight on gender.  Cardiovasc Res. 2002;  53 535-537
    CrossrefPubMedGoogle Scholar
  • 9 Conroy RM, Pyörälä K, Fitzgerald AP. et al. . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.  Eur Heart J. 2003;  24 987-1003
    CrossrefPubMedGoogle Scholar
  • 10 Coronary Drug Project Research Group . The Coronary Drug Project. Findings leading to discontinuation of the 2,5 mg day estrogen group.  JAMA. 1973;  226 652-657
    CrossrefPubMedGoogle Scholar
  • 11 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
    CrossrefPubMedGoogle Scholar
  • 12 Feldman HA, Johannes CB, Araujo AB. et al. . Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study.  Am J Epidemiol. 2001;  153 79-89
    CrossrefPubMedGoogle Scholar
  • 13 Freedman S, Srinivasan DS, Webber LS. Black-white differences in serum lipoproteins during sexual maturation: The Bogalusa Heart Study.  J Chron Dis. 1987;  40 309-318
    CrossrefPubMedGoogle Scholar
  • 14 Gibbons RJ, Chatterjee K, Daley J. et al. . ACC/AHA/ACP-ASIM Guidelines for the management of patients with chronic stable angina.  J Am Coll Cardiol. 1999;  33 2092-2190
    CrossrefPubMedGoogle Scholar
  • 15 Hak AE, Witteman JCM, de Jong FH. et al. . Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam Study.  J Clin Endocrinol Metab. 2002;  87 3632-3639
    CrossrefPubMedGoogle Scholar
  • 16 Hamilton JB, Mestler GE. Mortality and survival: comparison of eunuchs with intact men and women in a mentally retarded population.  J Gerontol. 1969;  24 395-411
    PubMedGoogle Scholar
  • 17 Harman SM, Metter EJ, Tobin JD. et al. . Longitudinal effects of aging on serum total and free testosterone levels in healthy men.  J Clin Endocrinol Metab. 2001;  86 724-731
    CrossrefPubMedGoogle Scholar
  • 18 Hatakeyama N, Nishizawa M, Nakagawa A. et al. . Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells.  FEBS Lett. 2002;  530 129-132
    CrossrefPubMedGoogle Scholar
  • 19 Herbst KL, Amory JK, Brunzell JD. et al. . Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk.  Am J Physiol Endocrinol Metab. 2003;  284 E1112-E1118
    PubMedGoogle Scholar
  • 20 Jenkins JS. The voice of the castrato.  Lancet. 1998;  3521 1877-1880
    PubMedGoogle Scholar
  • 21 Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies.  Steroids. 1990;  55 330-352
    CrossrefPubMedGoogle Scholar
  • 22 Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus.  Arch Intern Med. 2002;  162 1737-1745
    CrossrefPubMedGoogle Scholar
  • 23 Kaplan NM. Clinical hypertension (7th edition). Baltimore, Maryland: Williams & Wilkins 1998
    Google Scholar
  • 24 Keil U, Fitzgerald AP, Wellmann J, Hense HW. Risikoabschätzung tödlicher Herz-Kreislauf-Erkrankungen.  Dtsch Ärzteblatt. 2005;  102 A1808-A1812
    PubMedGoogle Scholar
  • 25 Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham Population.  Am J Cardiol. 1986;  111 383-390
    CrossrefPubMedGoogle Scholar
  • 26 Levy D, Kannel WB. Cardiovascular risks: new insights from Framingham.  Am Heart J. 1988;  116 266-272
    CrossrefPubMedGoogle Scholar
  • 27 Levy D, Kannel WB. Searching for answers to ethnic disparities in cardiovascular risk.  Lancet. 2000;  356 266-267
    CrossrefPubMedGoogle Scholar
  • 28 Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular death.  Endocrin Rev. 2003;  24 313-340
    CrossrefPubMedGoogle Scholar
  • 29 Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease.  Lancet. 1999;  353 89-92
    CrossrefPubMedGoogle Scholar
  • 30 Mäkinen J, Järvisalo MJ, Pöllänen P. et al. . Increased carotid atherosclerosis in andropausal middle-aged men.  J Am Coll Cardiol. 2005;  45 1603-1608
    CrossrefPubMedGoogle Scholar
  • 31 Morrison JA, Laskarzewski PM, Rauh JL. Lipids, lipoproteins, and sexual maturation during adolescence: The Princeton Maturation Study.  Metabolism. 1979;  28 641-649
    CrossrefPubMedGoogle Scholar
  • 32 Morrison JA, Sprecher DL, Biro FM. et al. . Serum testosterone associates with lower high density lipoprotein cholesterol in black and white males, 10-15 years of age, through lowered apolipoproten AI and AII concentrations.  Metabolism. 2002;  51 432-437
    CrossrefPubMedGoogle Scholar
  • 33 Mosca L, Manson JE, Sutherland SE. et al. . Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association.  Circulation. 1997;  96 2468-2482
    CrossrefPubMedGoogle Scholar
  • 34 Muller M, van den Beld AW, Bots ML. et al. . Endogenous sex hormones and progression of carotid atherosclerosis in elderly men.  Circulation. 2004;  109 2074-2079
    CrossrefPubMedGoogle Scholar
  • 35 Natarajan S, Liao Y, Cao G. et al. . Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease.  Arch Intern Med. 2003;  163 1735-1740
    CrossrefPubMedGoogle Scholar
  • 36 Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone.  Nature. 1993;  366 1011-1017
    PubMedGoogle Scholar
  • 37 Reinecke H, Bogdanski J, Woltering A. et al. . Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women.  Am J Cardiol. 2002;  90 364-368
    CrossrefPubMedGoogle Scholar
  • 38 Rich-Edwards JW, Manson JA, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women.  N Engl J Med. 1995;  332 1758-1766
    CrossrefPubMedGoogle Scholar
  • 39 Rossouw JE. Women and coronary heart disease. In: DJ Betteridge (ed). Lipids and vascular disease - current issues. London: Martin Dunitz Ltd, UK 2000
    Google Scholar
  • 40 The Veterans Administration Co-operative Urological Research Group. . Treatment and survival of patients with cancer of the prostate.  Surg Gynecol Obstet. 1967;  124 1011-1017
    PubMedGoogle Scholar
  • 41 The World Health Report. Geneva: World Health Organization 2002
    Google Scholar
  • 42 Van Kesteren PJ, Ascheman H, Megens JA. et al. . Mortality and Morbidity in transsexual subjects treated with cross-sex hormones.  Clin Endocrinol (Oxf). 1997;  47 337-342
    CrossrefPubMedGoogle Scholar
  • 43 Vasan RS, Larson MG, Leip EP. et al. . Impact of high-normal blood pressure on the risk of cardiovascular disease.  N Engl J Med. 2002;  345 1291-1297
    PubMedGoogle Scholar
  • 44 Weidemann W, Hanke H. Cardiovascular effects of androgens.  Cardiovasc Drug Rev. 2002;  20 175-198
    PubMedGoogle Scholar
  • 45 Wilson JD, Roehrborn C. Long-term consequence of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts.  J Clin Endocrinol Metab. 1999;  84 4324-4331
    CrossrefPubMedGoogle Scholar
  • 46 Wu FCW, von Eckardstein A. Androgens and coronary artery disease.  Endocr Rev. 2003;  24 183-187
    CrossrefPubMedGoogle Scholar
  • 47 Yarnell JWG, Beswick AD, Sweetnam PM, Riad-Fahmy D. Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study.  Arterioscler Thromb. 1993;  13 517-520
    CrossrefPubMedGoogle Scholar
  • 48 Zitzman M, Nieschlag E. Testosterone levels in healthy men and their relation to behavioural and physical characteristics: facts and constructs.  Eur J Endocrinol. 2001;  144 183-187
    CrossrefPubMedGoogle Scholar

1 National Cholesterol Education Program

2 PROspective CArdiovascular Münster Studie

3 Lipid Research Clinics Coronary Primary Prevention Trial

Anschrift des Verfassers

Prof. Dr. Dietrich Strödter

Innere Medizin/Kardiologie

Medizinische Klinik I, Universität Gießen

Klinikstr. 36, 35385 Gießen